<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085475</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62027</org_study_id>
    <secondary_id>EORTC-62027</secondary_id>
    <secondary_id>EUDRACT-2004-002538-20</secondary_id>
    <nct_id>NCT00085475</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma</brief_title>
  <official_title>Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes&#xD;
      necessary for their growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating&#xD;
      patients with locally advanced or metastatic dermatofibrosarcoma protuberans or giant cell&#xD;
      fibroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the therapeutic activity of imatinib mesylate in patients with locally&#xD;
           advanced or metastatic dermatofibrosarcoma protuberans or giant cell fibroblastoma.&#xD;
&#xD;
        -  Determine the progression-free rate at 14 weeks in patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine objective response rate, progression-free survival, and overall survival in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, multicenter study.&#xD;
&#xD;
      Patients receive oral imatinib mesylate twice daily for at least 14 weeks in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients with stable disease after 14 weeks&#xD;
      receive imatinib mesylate for 12 additional weeks. Patients with a partial or complete&#xD;
      response at 14 weeks undergo surgical resection if possible. If surgical resection of all&#xD;
      remaining tumor is not possible OR if complete resection is not achieved (section margins&#xD;
      positive), patients continue to receive imatinib mesylate in the absence of disease&#xD;
      progression&#xD;
&#xD;
      Patients are followed monthly for 6 months, every 3 months for 6 months, every 6 months for 2&#xD;
      years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free rate at 14 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate as assessed by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by CTC 3.0</measure>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed dermatofibrosarcoma protuberans or giant cell fibroblastoma&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Not amenable to surgery, radiotherapy, or combined modality therapy with curative&#xD;
             intent&#xD;
&#xD;
          -  Documented progressive disease within the past 3 months&#xD;
&#xD;
               -  Previously irradiated lesions must show disease progression&#xD;
&#xD;
          -  Tumor expressing COL1A1/PDGF-beta by fluorescence in situ hybridization&#xD;
&#xD;
               -  Translocation t(17;22)(q22;q13)&#xD;
&#xD;
          -  No prior chemotherapy OR previously treated with 1, and only 1, line of combination&#xD;
             chemotherapy with ifosfamide and doxorubicin OR 2 lines of single-agent therapy OR&#xD;
             relapsed within 6 months after adjuvant chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 mg/dL* NOTE: *Transfusion allowed&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if hepatic&#xD;
             metastases are present)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  No uncontrolled hepatic disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No uncontrolled renal disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No concurrent severe or uncontrolled medical disease&#xD;
&#xD;
          -  No medical, psychological, familial, sociological, or geographical condition that&#xD;
             would preclude study participation, compliance, or giving informed consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer currently in complete remission&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 28 days since prior biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent anticancer biologic agents&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 28 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
               -  Concurrent palliative radiotherapy allowed provided radiotherapy will not be&#xD;
                  administered to a target lesion&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 28 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation therapy with warfarin&#xD;
&#xD;
               -  Concurrent low-molecular weight heparin or mini-dose warfarin for prophylaxis of&#xD;
                  central venous catheter thrombosis allowed&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent cytostatic agents&#xD;
&#xD;
          -  No other concurrent tyrosine kinase inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan T. van Oosterom, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group; Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. doi: 10.1200/JCO.2009.25.7899. Epub 2010 Mar 1.</citation>
    <PMID>20194851</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Dermatofibrosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

